Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMG1A46 in Advanced B-cell Malignancies
NCT05348889Phase 2Terminated
- Sponsor
- Chengdu Chimagen Biosciences
- Start
- Aug 2022
- Primary completion
- Oct 2024
- Modality
- Antibody Conjugates, Trispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
A Phase 2 trial of 1A46 in non-Hodgkin lymphoma (NHL), acute lymphoblastic leukemia (ALL), sponsored by Chengdu Chimagen Biosciences. Started Aug 2022; status: terminated.
02
Drugs
1A46
03
Conditions
non-Hodgkin lymphoma (NHL)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT05348889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05348889.